Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Gemcitabine

5

II.c ARDS and the hemolytic-uremic syndrome (HUS)

2
Last update : 20/01/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Haemolytic uraemic syndrome associated with gemcitabine.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2010 May;12;381-3 2010 May
[Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
La Revue de medecine interne 2005 Mar;26;179-88 2005 Mar
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Anti-cancer drugs 2003 Sep;14;665-8 2003 Sep
Gemcitabine-associated hemolytic-uremic syndrome.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2002 Oct;40;E16 2002 Oct
Gemcitabine-associated diffuse alveolar hemorrhage.
Intensive care medicine 2001 Sep;27;1554 2001 Sep
A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.
Cancer 1999 May 01;85;2023-32 1999 May 01

Powered by

  • ^
  • Contact
  • Cookies
  • About